Arcutis Biotherapeutics Inc (NASDAQ:ARQT) price on Wednesday, February 05, rose 0.61% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $13.18.
A look at the stock’s price movement, the close in the last trading session was $13.10, moving within a range at $13.0101 and $13.39. The beta value (5-Year monthly) was 1.185. Turning to its 52-week performance, $16.20 and $5.38 were the 52-week high and 52-week low respectively. Overall, ARQT moved -9.85% over the past month.
Arcutis Biotherapeutics Inc’s market cap currently stands at around $1.54 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 60.52M for the company’s revenue for the quarter, with a low and high estimate of 53.6M and 63.52M respectively. The average forecast suggests up to a 347.41% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 185.49M, representing a 211.19% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ARQT is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend ARQT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ARQT’s current price about -3.84% and -1.51% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.74, while 7-day volatility ratio is 5.11% and 6.94% in the 30-day chart. Further, Arcutis Biotherapeutics Inc (ARQT) has a beta value of 1.50, and an average true range (ATR) of 0.91. Analysts have given the company’s stock an average 52-week price target of $19, forecast between a low of $19 and high of $19. Looking at the price targets, the low is -44.16% off current price level while to achieve the yearly target high, price needs to move -44.16%. Nonetheless, investors will most likely welcome a -44.16% jump to $19 which is the analysts’ median price.
If we refocus on Arcutis Biotherapeutics Inc (NASDAQ:ARQT), historical trading data shows that trading volumes averaged 1.92 over the past 10 days and 2.15 million over the past 3 months. The company’s latest data on shares outstanding shows there are 117.00 million shares.
The 12.02% of Arcutis Biotherapeutics Inc’s shares are in the hands of company insiders while institutional holders own 103.64% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 20.22 million on 2025-01-15, giving us a short ratio of 9.21. The data shows that as of 2025-01-15 short interest in Arcutis Biotherapeutics Inc (ARQT) stood at 2137.0000999999997 of shares outstanding, with shares short falling to 23.11 million registered in 2024-12-13. Current price change has pushed the stock -5.38% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ARQT stock continues to rise going into the next quarter.
